Xiaoyang Xue1, Xiaochuan Duan2, Mengyuan Qin3

  • 1Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, PR China.

PubMed
概括

含卡普马提尼布的水凝 (Cap-Gel) 通过抑制HGF/c-MET通路,有效地治疗角膜新血管化 (CNV). 这种新的治疗策略与单独使用卡普马提尼布相比,显示出更高的疗效,减少炎症和纤维化,改善视力.